Volume 12

Introduction, Dr. Roger A. Byrne, Dean From the Editor, Dr. Larissa Kat Tracy From the Designers, Rachel English, Rachel Hanson Immortality in the Mortal World: Otherworldly Intervention in Lanval and The Wife of Bath\u27s Tale by Haleigh James Analysis of Phenolic Compounds in Moroccan Olive Oils by HPLC by Hannah Meyls Art by Hope Irvin The Effects of Cell Phone Use on Gameplay Enjoyment and Frustration by Megan E. Hlavaty, Samara L. Gall, and Austin J. Funk Care, No Matter What: Planned Parenthood\u27s Use of Organizational Rhetoric to Expand its Reputation by Karyn Keane Analysis of Petroleum Products for Forensic and Environmental Applications by Sarah Ghali, Antonio Harvey, and Katelynn McCrillis Art by Andrew Jones The Triangle Shirtwaist Factory Fire by Rachel Hazelwood Art by Madison Schmitz Ercilla y la imitacion: Araucanos al estilo europeo by Marija Venta Design by Haley Tebo Design by Jeremiah Gilmer White Supremacist\u27s Appropriation of the Persuasion of Passivity in Marvel\u27s Captain America by Bridget Dunn Design by Benjamin Sullivan Art by McKenzie Johnso

Australasian emergency nurses\u27 willingness to attend work in a disaster: a survey

Abstract not availablePaul Arbon, Jamie Ranse, Lynette Cusack, Julie Considine, Ramon Z. Shaban, Richard J. Woodman, Laura Bahnisch, Mayumi Kako, Karen Hammad, Belinda Mitchel

TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer

Purpose: Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: Randomized 2:1 phase II trial of albumin-bound paclitaxel (nab-PAC) ± TIG in patients with TNBC stratified by prior chemotherapy. Patients received nab-PAC weekly × 3 ± TIG every other week, every 28 days. Primary objective was within-arm objective response rate (ORR). Secondary objectives were safety, progression-free survival (PFS), clinical benefit, and TIG immunogenicity. Metastatic research biopsies were required. Results: Among 64 patients (60 treated; TIG/nab-PAC n = 39 and nab-PAC n = 21), there were 3 complete remissions (CR), 8 partial remissions (PR; 1 almost CR), 11 stable diseases (SD), and 17 progressive diseases (PD) in the TIG/nab-PAC arm (ORR, 28%), and no CRs, 8 PRs, 4 SDs, and 9 PDs in the nab-PAC arm (ORR, 38%). There was a numerical increase in CRs and several patients had prolonged PFS (1,025+, 781, 672, 460, 334) in the TIG/nab-PAC arm. Grade 3 toxicities were 28% and 29%, respectively, with no grade 4–5. Exploratory analysis suggests an association of ROCK1 gene pathway activation with efficacy in the TIG/nab-PAC arm. Conclusions: ORR and PFS were similar in both. Preclinical activity of TIG in basal-like breast cancer and prolonged PFS in few patients in the combination arm support further investigation of anti-DR5 agents. ROCK pathway activation merits further evaluation